Agent for preventing or ameliorating alzheimer's disease

Patent metadata

Field	Value
Publication number	US-11998559-B2
Application number	US-201816756978-A
Country	US
Kind code	B2
Filing date	Oct 3, 2018
Priority date	Oct 18, 2017
Publication date	Jun 4, 2024
Grant date	Jun 4, 2024

Abstract

The purpose of the present invention is to provide an agent for preventing or ameliorating Alzheimer's disease, said agent being able to effectively suppress the accumulation of amyloid β proteins using a safe material, which has been used in foods for many years, and improve spontaneous alternation behavior change ratio. Ceramides (in particular, a glucosylceramide originating in Amorphophallus konjac ) can effectively suppress the accumulation of amyloid β proteins and thus enables the prevention or amelioration of Alzheimers disease.

First claim

The invention claimed is:

1. A method for ameliorating cognitive function in Alzheimer's disease to a person in need of amelioration of Alzheimer's disease and cognitive function, comprising a step of administering an effective amount of a ceramide to the person,
wherein the ceramide is derived from tuber of Amorphophallus konjac and wherein the ceramide comprises a glucosylceramide of 4,8-sphingadienine.

2. The method according to claim 1 , wherein the ceramide is in a form of food or beverage.

3. The method according to claim 1 , wherein the ceramide is in a form of pharmaceutical.

4. The method according to claim 1 , wherein a composition containing the ceramide with a content of 1 to 20% by mass is administered.

5. The method according to claim 1 , wherein a dosage of the ceramide is 0.6 to 10 mg per day.

6. The method according to claim 1 , wherein the glucosylceramide is a glucosylceramide of trans-4, cis-8-sphingadienine or trans-4-trans-8-sphingadienine.

7. The method according to claim 1 , wherein a composition containing the ceramide with a content of 1 to 20% by mass is administered, and
wherein a dosage of the ceramide is 0.6 to 10 mg per day.

Assignees

• Daicel Corp

Inventors

• Takahashi Kaori
• Mukai Katsuyuki
• Igarashi Yasuyuki
• Yuyama Kohei

Classifications

• A61K31/7032 Primary

  attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A23L33/105 Primary

  Plant extracts, their artificial duplicates or their derivatives · CPC title

• A61K31/7028

  Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages · CPC title

• A61K36/888

  Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage · CPC title